{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-139440","form_type":"8-K","ticker":"LNTH","cik":"0001521036","company_name":"Lantheus Holdings, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.803411+00:00","generated_at":"2026-06-01T22:59:49.523201+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Lantheus appoints new CMO and CSO; Humphrey and Provost roles change May 28","bullets":["Jeffrey S. Humphrey, MD appointed Chief Medical Officer; Jean-Claude Provost, MD named Chief Science Officer, both effective May 28, 2024.","Humphrey brings 30+ years clinical oncology experience from Bayer, Bristol-Myers Squibb, Kyowa Kirin, and Pfizer.","Provost transitions from CMO to CSO to lead business development and pipeline acceleration; holds medicine degree from Sorbonne University.","CEO Markison says moves will 'enable our team to accelerate innovation' in radiopharmaceutical diagnostics and therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-139440","json":"https://secwatch.observer/filing/0001193125-24-139440.json","markdown":"https://secwatch.observer/filing/0001193125-24-139440.md","text":"https://secwatch.observer/filing/0001193125-24-139440.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1521036/000119312524139440/0001193125-24-139440-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1521036/000119312524139440/d824247d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:59:49.523201+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"238f794c99","claim":"Jean-Claude Provost was appointed as Chief Science Officer at Lantheus Holdings, Inc..","evidence_excerpt":"On May 15, 2024, Lantheus Holdings, Inc. (the “Company”) announced that, upon the effectiveness of his appointment as Chief Science Officer of the Company on May 28, 2024, Jean-Claude Provost MD will no longer serve as the Company’s Chief Medical Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1521036/000119312524139440/0001193125-24-139440-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Science Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}